Rabeprazole sodium + Esomeprazole
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroesophageal Reflux Disease (GERD)
Conditions
Gastroesophageal Reflux Disease (GERD)
Trial Timeline
Feb 1, 2008 → Jan 1, 2010
NCT ID
NCT00658775About Rabeprazole sodium + Esomeprazole
Rabeprazole sodium + Esomeprazole is a phase 3 stage product being developed by Eisai for Gastroesophageal Reflux Disease (GERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00658775. Target conditions include Gastroesophageal Reflux Disease (GERD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00658775 | Phase 3 | Completed |
| NCT00658632 | Phase 3 | Completed |
| NCT00658528 | Phase 3 | Completed |
Competing Products
20 competing products in Gastroesophageal Reflux Disease (GERD)